ADAR1 Capital Management LLC Buys New Stake in Dyne Therapeutics, Inc. $DYN

Key Points

• ADAR1 Capital Management LLC has invested approximately $315,000 in Dyne Therapeutics by acquiring 30,099 shares of the company's stock.
• CEO John Cox purchased 100,000 shares of Dyne Therapeutics stock, increasing his ownership by 70.33% to a total value of about $2.2 million.
• Analysts have varied opinions on Dyne Therapeutics' stock, with price targets from major brokerages ranging from $13.00 to $66.00 and a consensus rating of "Buy".

ADAR1 Capital Management LLC acquired a new stake in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 30,099 shares of the company's stock, valued at approximately $315,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in DYN. Caitong International Asset Management Co. Ltd lifted its position in Dyne Therapeutics by 378.6% during the first quarter. Caitong International Asset Management Co. Ltd now owns 3,092 shares of the company's stock valued at $32,000 after purchasing an additional 2,446 shares during the period. Quarry LP bought a new position in Dyne Therapeutics during the first quarter valued at approximately $47,000. GF Fund Management CO. LTD. bought a new position in Dyne Therapeutics during the fourth quarter valued at approximately $50,000. E Fund Management Co. Ltd. lifted its position in Dyne Therapeutics by 16.2% during the first quarter. E Fund Management Co. Ltd. now owns 13,771 shares of the company's stock valued at $144,000 after purchasing an additional 1,923 shares during the period. Finally, AlphaQuest LLC bought a new position in Dyne Therapeutics during the first quarter valued at approximately $171,000. Institutional investors own 96.68% of the company's stock.

Analyst Ratings Changes

DYN has been the topic of a number of research analyst reports. JPMorgan Chase & Co. lowered their price objective on shares of Dyne Therapeutics from $10.00 to $9.00 and set a "neutral" rating on the stock in a research report on Tuesday, July 15th. Sanford C. Bernstein initiated coverage on shares of Dyne Therapeutics in a research report on Tuesday, June 24th. They set a "market perform" rating and a $13.00 price objective on the stock. Oppenheimer lowered their price objective on shares of Dyne Therapeutics from $34.00 to $13.00 and set an "outperform" rating on the stock in a research report on Wednesday, August 6th. Robert W. Baird decreased their price target on shares of Dyne Therapeutics from $46.00 to $32.00 and set an "outperform" rating on the stock in a research report on Wednesday, June 18th. Finally, Royal Bank Of Canada decreased their price target on shares of Dyne Therapeutics from $25.00 to $23.00 and set an "outperform" rating on the stock in a research report on Tuesday, July 29th. Three research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, Dyne Therapeutics has an average rating of "Buy" and a consensus target price of $34.07.

Insiders Place Their Bets

In related news, CEO John Cox bought 100,000 shares of the business's stock in a transaction that occurred on Monday, July 14th. The stock was bought at an average cost of $9.11 per share, with a total value of $911,000.00. Following the completion of the purchase, the chief executive officer owned 242,179 shares of the company's stock, valued at approximately $2,206,250.69. The trade was a 70.33% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 14.14% of the company's stock.

Dyne Therapeutics Price Performance

Shares of DYN stock traded down $0.24 on Thursday, hitting $13.24. 1,751,830 shares of the stock traded hands, compared to its average volume of 2,419,008. The firm has a market cap of $1.88 billion, a price-to-earnings ratio of -3.43 and a beta of 1.10. Dyne Therapeutics, Inc. has a 52 week low of $6.36 and a 52 week high of $37.08. The firm has a 50 day simple moving average of $10.70 and a two-hundred day simple moving average of $11.16. The company has a debt-to-equity ratio of 0.17, a current ratio of 16.83 and a quick ratio of 16.83.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last announced its quarterly earnings data on Monday, July 28th. The company reported ($0.97) EPS for the quarter, beating the consensus estimate of ($0.99) by $0.02. As a group, equities research analysts predict that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current fiscal year.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.